Hi, AK. Not posting much as my job has me very busy currently. Thought the cc was pretty his overall. Thinking of adding more at these levels, and keeping an eye on scrip growth.
Good pints Alan. A minor quibble: aspirin was derived from willow bark. Willow's genus is salix, as in salicylates. Aspirin is a acetyl salicylic acid, named for its derivation.
Jeff, gave you a thumbs up, as I appreciate knowing what's up. I think it may present yet another sale opportunity, though I grow a bit weary of them, lol. Don't get why people always want top shoot the messenger, especially one with your long history on this board.
FOr me, flat or lower proce is okay for the next several months, as I'm, buying on spec, in anticipation of Anchor results. If they bust, there goes my spec $$. If as I suspect, they are gamechanging, I'll do my part to help the economy.
I'm foreseeing a sharp drop into the close. Someone peeked!
Price is still affected by your peeking yesterday. Check back in a week, and it should be better if your behavior improves.
Post of the month. Despite that, I gave it thumbs down, because my thumb was too damn fat to hit the correct spot on my smart phone screen
I think the answer lies in your investment perspective. While I am surprised at the price here, I continue to expect a buyout longer term-in the next year or so--for over $20. While I never expected to be underwater, since my cost average is in the mid 7s. the fact that I am at this point does not have me panicked. It did cause a reassessment of my position, but that reaffirmed my belief that over time this drug and company become substantially more valuable than they are today. Trying to time selling all you own now to buy back to save a buck rsiks missing some big gains.
The jump could happen at any to me, even though I think it is several months off. When it comes, share price could run several dollars. For me, with a longer term view, I may add here, but I'm not selling. I'll sell when my belief in the fundamentals of the company change, or when the price is north of $20
Gotta love calling a 'sell' for a company near its 52-week low, and with PDUFA approval and acknowledged best-in-class dug, with a multi-billion $$ market, on the market and growing share daily.
$7.92 did't hold, but the good news--I hope--is that my standing order for April 8s at 46 cents filled. Of course, now I need the price to go up a bit by the anniversary of Paul Revere's ride...
Spot on, Venus. Thanks for posting. JL added a lot to this board's info, and those in denial of that are either fooling themselves or flat-out spreading FUD, in the time-honored tradition of bashers everywhere.
That's not to say JL was always easy to deal with, but we're all (supposed to be) adults here. Hard to tell that oftentimes, though.
An eye for an eye will leave everyone blind...ML King, Jr.
Harvey, thanks for the response. Things look great for Vascepa; it's only a matter of when, not if. AMRN is teaching me more about patience than I think I need to know...
Thanks for the info. Can you have provide examples of other drug launches, and timeframes until tier 2 obtained? This would be helpful in appraising Amarin management performance in the Vascepa launch. In particular, providing data to back up your post would go a long way towards undermining one line of bashing.
It could be April; I just see more catalysts in May, though the FDA is largely immune to those, so who knows. And your reply was along the lines of my first reaction, as in person I have a tendency towards wise-a*sness, but on these boards I try to reply for the benefit of people genuinely seeking info for their investing decisions, not necessarily to the author of a given question.
Sometimes I succeed, sometimes I cannot bite my tongue ;)
No one knows when NCE determination will be made. We know it will not be published this month, as the FDA put the OB listings on March 13. Next strong candidate for OB inclusion is May, imo...but it almost won't matter by then. Scrip data is developing, tier 2 movement is occurring, price will be more determined by that info going forward...